Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
Open Access

Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

Florentino Carral San Laureano, Mariana Tomé Fernández-Ladreda, Ana Isabel Jiménez Millán, Concepción García Calzado, María del Carmen Ayala Ortega
DOI: 10.1136/jim-2020-001633 Published 1 June 2021
Florentino Carral San Laureano
Endocrinology and Nutrition, University Hospital of Puerto Real, Puerto Real, Andalucía, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florentino Carral San Laureano
Mariana Tomé Fernández-Ladreda
Endocrinology and Nutrition, University Hospital of Puerto Real, Puerto Real, Andalucía, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Isabel Jiménez Millán
Endocrinology and Nutrition, University Hospital of Puerto Real, Puerto Real, Andalucía, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Concepción García Calzado
Endocrinology and Nutrition, University Hospital of Puerto Real, Puerto Real, Andalucía, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María del Carmen Ayala Ortega
Endocrinology and Nutrition, University Hospital of Puerto Real, Puerto Real, Andalucía, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1

    Clinical characteristics and chronic complications in T1D (n=412)

    All patients
    (n=412)
    Glargine U300 (n=187)Degludec
    (n=225)
    P value
    Age (years)37.0±13.437.7±14.136.6±12.80.376
    Gender male214 (52%)111 (59.4%)103 (45.8%)0.004
    Diabetes duration (years)18.7±12.317.6±12.619.8±11.90.112
    Weight (kg)72.0±14.971.7±13.772.3±15.90.759
    BMI (kg/m2)25.3±4.625.1±4.525.4±4.80.551
    HbA1c (%)7.8±1.47.6±1.28.1±1.5<0.001
     Patients with HbA1c ≤7%113 (27.4%)65 (35.3%)48 (21.5%)0.001
     Patients with HbA1c ≥8%148 (35.9%)53 (28.3%)95 (42.2%)0.003
    Carbohydrate counting (%)106 (25.7%)47 (25.1%)59 (26.2%)0.458
    Patients with FSL (%)80 (19.0%)27 (14.4%)44 (19.6%)0.107
     Time in range 70–180 mg/dL (%)47.3±18.051.1±14.645.0±19.50.183
     Time in hypoglycemia <70 mg/dL (%)6.8±6.69.2±8.35.8±4.40.053
     Time in hyperglycemia >180 mg/dL (%)46.5±19.939.6±16.450.5±20.70.023
    Active smoking (%)101 (24.5%)44 (23.5%)57 (25.3%)0.379
    Antihypertensive treatment (%)78 (18.9%)33 (17.6%)45 (20.0%)0.307
    Lipid-lowering treatment (%)147 (35.7%)65 (34.7%)82 (36.4%)0.349
    Diabetic retinopathy (%)194 (47.0%)79 (42.2%)115 (51.1%)0.056
     DR mild-to-moderate114 (27.6%)43 (23.0%)71 (31.5%)
     Laser therapy53 (12.9%)29 (15.5%)24 (10.6%)
     Surgery27 (6.6%)7 (3.6%)20 (8.9%)
    Diabetic nephropathy52 (12.6%)20 (10.7%)32 (14.2%)0.327
     Albuminuria42 (10.2%)16 (8.6%)26 (11.6%)
     Dialysis of kidney transplant10 (2.4%)4 (2.1%)6 (2.7%)
    Macrovascular complications (%)23 (5.6%)9 (4.8%)14 (6.2%)0.089
    • BMI, body mass index; DR, diabetic retinopathy; FSL, freestyle libre; HbA1c, glycosylated hemoglobin; T1D, type 1 diabetes.

  • Table 2

    Non-insulin hypoglycemic agents and daily insulin doses requirements in T1D using glargine U300 or degludec (n=412)

    All patients
    (n=412)
    Glargine U300 (n=187)Degludec
    (n=225)
    P value
    Non-insulin antidiabetics (%)30 (7.3)11 (5.9)19 (8.4)0.233
    Basal insulin
     Unit/day31.5±16.930.1±14.932.2±18.40.759
     Unit/kg/day0.43±0.200.43±0.190.44±0.210.563
    Prandial insulin
     Unit/day23.5±16.922.5±16.123.2±16.00.603
     Unit/kg/day0.33±0.230.32±0.230.33±0.200.851
    Total insulin
     Unit/day54.0±29.152.8±27.455.4±29.50.383
     Unit/kg/day0.77±0.360.76±0.350.76±0.330.683
    Basal/Total insulin ratio0.58±0.140.59±0.140.58±0.140.441
    • T1D, type 1 diabetes.

  • Table 3

    Daily insulin doses requirements by metabolic control subgroups in T1D using glargine U300 or degludec

    HbA1c ≤7%
    (IGla: 65 P; IDeg: 48 P)
    HbA1c 7.1%–8%
    (IGla: 69 P; IDeg: 82 P)
    HbA1c ≥8%
    (IGla: 53 P; IDeg: 95 P)
      P value P value P value
    Basal insulin
    Unit/day
     IGla-30025.8±13.40.78130.8±15.70.78035.1±13.80.779
     IDeg26.6±16.831.6±19.035.8±18.1
    Unit/kg/day
     IGla-3000.36±0.160.5580.43±0.170.8700.51±0.180.643
     IDeg0.38±0.200.42±0.210.49±0.21
    Prandial insulin
    Unit/day
     IGla-30018.7±12.40.55225.1±19.90.05524.5±14.60.185
     IDeg20.0±9.819.7±11.128.4±20.2
    Unit/kg/day
     IGla-3000.26±0.170.4040.35±0.270.0700.37±0.210.451
     IDeg0.29±0.110.27±0.160.40±0.26
    Total insulin
    Unit/day
     IGla-30044.7±22.20.89356.2±32.30.28559.6±24.70.342
     IDeg45.3±24.151.0±25.164.3±33.2
    Unit/kg/day
     IGla-3000.64±0.290.8570.79±0.370.1350.88±0.340.782
     IDeg0.64±0.240.69±0.280.89±0.38
    B/T ratio
     IGla-3000.60±0.150.0320.58±0.150.2170.60±0.130.269
     IDeg0.55±0.110.61±0.140.57±0.15
    • B/T, basal/total insulin; HbA1c, glycosylated hemoglobin; IDeg, insulina degludec; IGla-300, insulina glargina 300 UI/mL; P, patients; T1D, type 1 diabetes.

PreviousNext
Back to top
Vol 69 Issue 5 Table of Contents
Journal of Investigative Medicine: 69 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • AFMR Highlights
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice
Florentino Carral San Laureano, Mariana Tomé Fernández-Ladreda, Ana Isabel Jiménez Millán, Concepción García Calzado, María del Carmen Ayala Ortega
Journal of Investigative Medicine Jun 2021, 69 (5) 983-988; DOI: 10.1136/jim-2020-001633

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice
Florentino Carral San Laureano, Mariana Tomé Fernández-Ladreda, Ana Isabel Jiménez Millán, Concepción García Calzado, María del Carmen Ayala Ortega
Journal of Investigative Medicine Jun 2021, 69 (5) 983-988; DOI: 10.1136/jim-2020-001633
Download PDF

Share
Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice
Florentino Carral San Laureano, Mariana Tomé Fernández-Ladreda, Ana Isabel Jiménez Millán, Concepción García Calzado, María del Carmen Ayala Ortega
Journal of Investigative Medicine Jun 2021, 69 (5) 983-988; DOI: 10.1136/jim-2020-001633
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Data availability statement
    • Ethics statements
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Evaluating reporting of patient-reported outcomes in randomized controlled trials regarding inflammatory bowel disease: a methodological study
  • Effects of statins on outcomes in Hispanic patients with COVID-19
  • Serum levels of IL-37 and correlation with inflammatory cytokines and clinical outcomes in patients with coronary artery disease
Show more Original research

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2023 American Federation for Medical Research